home / stock / xfor / xfor news

XFOR News and Press, X4 Pharmaceuticals Inc. From 08/10/23

Stock Information
Company Name: X4 Pharmaceuticals Inc.
Stock Symbol: XFOR
Market: NYSE
Website: x4pharma.com
Menu
XFOR XFOR Quote XFOR Short XFOR News XFOR Articles XFOR Message Board
Get XFOR Alerts

News, Short Squeeze, Breakout and More Instantly...
XFOR - LGHL and EBIX among mid-day movers

2023-08-10 13:25:55 ET Gainers: WeWork ( WE ) +87% . Capri Holdings Limited ( CPRI ) +56% . Black Spade Acquisition ( BSAQ ) +58% . Edible Garden AG Incorporated ( EDBL ) +43% . Lion Group Holding Ltd. ( LGHL ) +37% . Precige...
XFOR - X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Earnings Call Transcript

2023-08-10 12:38:10 ET X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Results Conference Call August 10, 2023 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Murray Stewart - Interim CMO Mark Baldry - CCO C...

XFOR - LifeMD, Precigen top healthcare gainers; Galera, Virios lead losers' pack

2023-08-10 10:27:32 ET Gainers: LifeMD ( LFMD ) +20% . Precigen ( PGEN ) +19% . Repare Therapeutics ( RPTX ) +16% . Cosmos Health ( COSM ) +13% . GoodRx Holdings ( GDRX ) +13% . Losers: Galera Therapeutics ( GRTX ) -...

XFOR - ONDS, UP and HOTH among pre-market losers

2023-08-10 08:25:22 ET Galera Therapeutics ( GRTX ) -82% . Origin Materials ( ORGN ) -57% after Q2 earning release . Organogenesis Holdings ( ORGO ) -32% after Q2 earning release . Renovaro Biosciences ( RENB ) -23% . Wolverine World...
XFOR - X4 Pharmaceuticals GAAP EPS of -$0.33 misses by $0.16

2023-08-10 06:08:02 ET X4 Pharmaceuticals press release ( NASDAQ: XFOR ): Q2 GAAP EPS of -$0.33 misses by $0.16 . X4 had $142.3 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2023. For further details see: X4 Phar...

XFOR - X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

Submission of first U.S. New Drug Application for mavorixafor in WHIM syndrome on track for early 2H 2023 Emerging data from ongoing Phase 2 trial in certain chronic neutropenic disorders show mavorixafor durably increased neutrophil counts and enabled reductions in G-CSF dosing ...

XFOR - X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that Christophe Arbet-Engels, MD, PhD, will be joining ...
XFOR - X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules ...

XFOR - X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the sec...

XFOR - X4 Pharmaceuticals: Mavorixafor Could Change Chronic Neutropenic Treatment Landscape

2023-06-23 12:32:02 ET Summary The new drug application submission of mavorixafor for the treatment of patients with WHIM syndrome is expected in the 2nd half of 2023. Results from an ongoing phase 2 study using mavorixafor for idiopathic, cyclic, or congenital chronic neutropenia...
Previous 10 Next 10